peginterferon alfa 2b

BIOLOGICAL2 trials

Sponsors

FGK Clinical Research GmbH, Merck Sharp & Dohme LLC

Conditions

Hepatitis C, Chronic

Phase 2

A Pharmacokinetics/Pharmacodynamics Study of SCH 900518 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C (Protocol No. P05104AM2)(COMPLETED)

CompletedNCT00797745

Merck Sharp & Dohme LLCHepatitis C, Chronic

Start: 2008-11-30End: 2010-09-30Updated: 2015-01-22

Phase 4

Individually Adapted Therapy Duration for the Treatment of Chronic Hepatitis C Genotype 1 Infection

CompletedNCT00351403

FGK Clinical Research GmbHHepatitis C, Chronic

Start: 2006-07-31End: 2010-01-31Target: 390Updated: 2010-02-08